Assembly Biosciences (ASMB) Receives New Coverage from Analysts at Leerink Swann

Leerink Swann initiated coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report report published on Monday, MarketBeat reports. The firm issued an outperform rating and a $45.00 price target on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Assembly Biosciences’ Q4 2018 earnings at ($0.98) EPS, FY2018 earnings at ($3.93) EPS, Q1 2019 earnings at ($1.07) EPS, Q2 2019 earnings at ($1.08) EPS, Q3 2019 earnings at ($1.20) EPS, Q4 2019 earnings at ($1.10) EPS, FY2019 earnings at ($4.44) EPS, FY2020 earnings at ($5.83) EPS, FY2021 earnings at ($6.52) EPS and FY2022 earnings at ($4.59) EPS.

ASMB has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Assembly Biosciences from a hold rating to a buy rating and set a $26.00 target price on the stock in a research note on Tuesday, November 13th. Chardan Capital reiterated a neutral rating on shares of Assembly Biosciences in a report on Sunday, October 28th. BidaskClub upgraded shares of Assembly Biosciences from a strong sell rating to a sell rating in a report on Saturday, November 3rd. ValuEngine downgraded shares of Assembly Biosciences from a buy rating to a hold rating in a report on Wednesday, October 3rd. Finally, B. Riley upgraded shares of Assembly Biosciences from a neutral rating to a buy rating and set a $42.00 price target on the stock in a report on Monday, October 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $52.00.

ASMB opened at $25.10 on Monday. Assembly Biosciences has a fifty-two week low of $20.61 and a fifty-two week high of $67.36. The firm has a market cap of $620.28 million, a P/E ratio of -10.41 and a beta of 1.43.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.14. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%. The company had revenue of $4.29 million for the quarter, compared to analysts’ expectations of $3.21 million. As a group, research analysts expect that Assembly Biosciences will post -3.92 earnings per share for the current year.

In other Assembly Biosciences news, VP Uri A. Lopatin sold 15,204 shares of Assembly Biosciences stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $40.09, for a total value of $609,528.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 18.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. Allianz Asset Management GmbH bought a new stake in Assembly Biosciences in the 1st quarter valued at $2,130,000. Bank of Montreal Can bought a new stake in Assembly Biosciences in the 2nd quarter valued at $145,000. Fred Alger Management Inc. increased its holdings in Assembly Biosciences by 42.9% in the 2nd quarter. Fred Alger Management Inc. now owns 10,000 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 3,000 shares during the last quarter. Capital Impact Advisors LLC increased its holdings in Assembly Biosciences by 27.7% in the 2nd quarter. Capital Impact Advisors LLC now owns 40,682 shares of the biopharmaceutical company’s stock valued at $1,598,000 after acquiring an additional 8,819 shares during the last quarter. Finally, TD Asset Management Inc. increased its holdings in Assembly Biosciences by 20.5% in the 2nd quarter. TD Asset Management Inc. now owns 9,400 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors own 73.65% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Read More: What is the Ex-Dividend Date in Investing?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply